Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation

NCT01208961 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Severe Hypertriglyceridemia

Interventions

DRUG: Epanova (4 g) and Lovaza (4 g)
DRUG: Lovaza (4 g) and Epanova (4 g)

Sponsor

AstraZeneca

Collaborators

[object Object]